Alk Positive Metastatic Non Small Cell Lung Cancer Therapeutics
1. Alecensa patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9126931 | HOFFMANN-LA ROCHE | Tetracyclic compound |
May, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10350214 | HOFFMANN-LA ROCHE | Preparation containing tetracyclic compound at high dose |
Apr, 2035
(9 years from now) | |
| US11433076 | HOFFMANN-LA ROCHE | Preparation containing tetracyclic compound at high dose |
Apr, 2035
(9 years from now) | |
| US9440922 | HOFFMANN-LA ROCHE | Tetracyclic compound |
Jun, 2030
(4 years from now) | |
| US9365514 | HOFFMANN-LA ROCHE | Composition comprising tetracyclic compound |
Mar, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-756) | Nov 06, 2020 |
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2020 |
| Orphan Drug Exclusivity(ODE-105) | Dec 11, 2022 |
| Orphan Drug Exclusivity(ODE) | Nov 06, 2024 |
| Orphan Drug Exclusivity(ODE-159) | Nov 06, 2024 |
| New Indication(I-947) | Apr 18, 2027 |
| Orphan Drug Exclusivity(ODE-477) | Apr 18, 2031 |
Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2019
Market Authorisation Date: 11 December, 2015
Dosage: CAPSULE
How can I launch a generic of ALECENSA before it's drug patent expiration?
More Information on Dosage
ALECENSA family patents
2. Alunbrig patent expiration
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
ALUNBRIG's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10385078 | TAKEDA PHARMS USA | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine |
Nov, 2035
(9 years from now) | |
| US9012462 | TAKEDA PHARMS USA | Phosphorous derivatives as kinase inhibitors |
Apr, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9611283 | TAKEDA PHARMS USA | Methods for inhibiting cell proliferation in ALK-driven cancers |
Apr, 2034
(8 years from now) | |
| US9273077 | TAKEDA PHARMS USA | Phosphorus derivatives as kinase inhibitors |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| New Indication(I-847) | May 22, 2023 |
| Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-142) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-300) | May 22, 2027 |
Drugs and Companies using BRIGATINIB ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Dosage: TABLET
More Information on Dosage
ALUNBRIG family patents
3. Lorbrena patent
expiration
Treatment: Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test
Can you believe LORBRENA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10420749 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(10 years from now) | |
| US8680111 | PFIZER | Macrocyclic derivatives for the treatment of diseases |
Mar, 2033
(7 years from now) | |
| US11299500 | PFIZER | Crystalline form of lorlatinib free base hydrate |
Oct, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020376 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 02, 2023 |
| New Indication(I-847) | Mar 03, 2024 |
| Orphan Drug Exclusivity(ODE-217) | Nov 02, 2025 |
| Orphan Drug Exclusivity(ODE-218) | Nov 02, 2025 |
| Orphan Drug Exclusivity(ODE-219) | Nov 02, 2025 |
| Orphan Drug Exclusivity(ODE-349) | Mar 03, 2028 |
Drugs and Companies using LORLATINIB ingredient
NCE-1 date: 02 November, 2022
Market Authorisation Date: 02 November, 2018
Dosage: TABLET
More Information on Dosage
LORBRENA family patents
4. Zykadia patent expiration
Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk); Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-...
ZYKADIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8039474 | NOVARTIS | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists |
Jun, 2030
(4 years from now) | |
| US7153964 | NOVARTIS | Pyrimidine compounds |
Feb, 2021
(4 years ago) | |
| US8188276 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(2 years ago) | |
| US8835430 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(2 years ago) | |
| US9416112 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(2 years ago) | |
| US9018204 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(2 years ago) | |
| US7893074 | NOVARTIS | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2026
(3 months from now) | |
| US8039479 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Jun, 2030
(4 years from now) | |
| US8399450 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(1 year, 10 months from now) | |
| US7964592 | NOVARTIS | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2028
(2 years from now) | |
| US9309229 | NOVARTIS | Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
Jan, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377921 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(1 year, 10 months from now) | |
| US8703787 | NOVARTIS | Methods of using ALK inhibitors |
Feb, 2032
(6 years from now) | |
| US12357630 | NOVARTIS | NA |
Dec, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2019 |
| M(M-199) | May 26, 2020 |
| Orphan Drug Exclusivity(ODE-66) | Apr 29, 2021 |
| Orphan Drug Exclusivity(ODE) | May 26, 2024 |
| ODE*(ODE*) | May 26, 2024 |
| Orphan Drug Exclusivity(ODE-145) | May 26, 2024 |
Drugs and Companies using CERITINIB ingredient
NCE-1 date: 29 April, 2018
Market Authorisation Date: 29 April, 2014
Dosage: CAPSULE
More Information on Dosage
ZYKADIA family patents